Healthcare >> Sector Roundtables >> October 1, 2001
MICHAEL G. KING, JR. is a Managing Director and Senior Biotechnology
Analyst at Robertson Stephens. He focuses on the genomics sector. Prior
to joining Robertson Stephens he was a Senior Biotechnology Analyst at
Vector Securities International and served as Vice President of
Research, Biotechnology, with Dillon, Read & Co., Inc. Mr. King also has
been a Senior Vice President of Sales at Alex. Brown and Sons. In 2001,
he ranked fourth for his stock-picking accuracy in The Wall Street
Journal's annual 'Best on the Street' survey. In 2000, Mr. King was
given the Institutional Investor Home Run Hitter award for his coverage
of OSI Pharmaceuticals. He holds a BBA degree from Baruch College. Profile
ELISE T. WANG is currently a Managing Director in Equity Research at
Salomon Smith Barney covering the biotechnology industry. Previously,
she was a Managing Director and Senior Research Analyst in the Health
Care Equity Research Group at PaineWebber Incorporated, covering the
biotechnology industry. In 2000, Ms. Wang was voted runner-up in the
Institutional Investor poll in Biotechnology. In addition, Ms. Wang also
achieved recognition in the Wall Street Journal All Star Analyst survey
in Biotechnology for the past three years. Prior to joining Equity
Research at PaineWebber in January of 1996, she was a Vice President in
the Health Sciences Group of the Investment Banking Division of
PaineWebber with responsibility for providing financial advisory work
and services in biotechnology and other healthcare sectors. Ms. Wang
holds a Bachelor of Arts degree in Engineering Sciences with a specialty
in Biomechanics from Harvard University and a Master of Business
Administration degree from Harvard Graduate School of Business. Profile
DR. PETER F. DRAKE is a Managing Director and Senior Biotechnology
Analyst at Prudential Securities, Inc. He was a co-Founder and Executive
Vice President of Vector Securities International, Inc., which was
acquired in July 1999 by Prudential Securities, Inc. Prior to this, Dr.
Drake was a Partner with Kidder Peabody and Company and was its Senior
Research Analyst covering biotechnology and biomedical products from
1980-1983. Dr. Drake has published extensively on the biotechnology
industry. He has been consistently ranked among the leading analysts on
Wall Street by Institutional Investor magazine most recently as the
number one analyst among regional research boutiques, while at Vector
Securities International Inc. 1995-1999. Dr. Drake holds a PhD in
Neurobiology and Biochemistry from Bryn College, and a CBA from the
Wharton School of Business at the University of Pennsylvania, and
performed his undergraduate work at Bowdoin College where he majored in
Biology and Russian. Profile
DR. MARY ANN GRAY has been with the Federated Kaufmann Fund for the past
two years, focusing on both public and private healthcare investments.
Prior to joining the Kaufmann Fund, Dr. Gray was a sell side
Biotechnology Analyst for nine years with Kidder Peabody; Dillon, Read;
and Raymond James. Earlier in her career, Dr. Gray managed preclinical
toxicology studies for the National Cancer Institute through Battelle
Memorial Institute and worked in a hospital laboratory. She did
postdoctoral work at Northwestern University Medical School and Yale
University School of Medicine. She held scientific positions at
Schering-Plough and NeoRx. Dr. Gray has a PhD in Pharmacology from the
University of Vermont where she focused on novel chemotherapeutic agents
for the treatment of cancer. Profile
several years? What are the sectors that should be included in a
discussion of biotechnology today?
Ms. Wang: An important
